Real World Evidence of the Safety and Clinical Practice Use of Maviret in Adolescents Patients Infected With Chronic Hepatitis C Virus (All Case Survey)
Status: Completed
Location: See all (54) locations...
Study Type: Observational
SUMMARY
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 17
Healthy Volunteers: f
View:
• Chronic Hepatitis C Virus (HCV) infection treated in daily practice with Maviret
• Enrolled after Maviret treatment begins
• Prior treatment with Maviret
Locations
Other Locations
Japan
Hyogo Prefectural Amagasaki General Medical Center /ID# 239388
Amagasaki-shi
Hyogo Prefectural Amagasaki General Medical Center /ID# 261350
Amagasaki-shi
Chiba University Hospital /ID# 225889
Chiba
Tokyo Metropolitan Children's Medical Center /ID# 258142
Fuchu-shi
Yamada Clinic /ID# 225909
Fujisawa-shi
Kyushu University Hospital /ID# 261351
Fukuoka
Gifu Municipal Hospital /ID# 225890
Gifu
Tamakoshi Clinic /ID# 224113
Hamamatsu
Hirosaki University Hospital /ID# 262654
Hirosaki-shi
Okanami General Hospital /ID# 256995
Iga-shi
Nara Hospital Kinki University Faculty of Medicine, /ID# 224609
Ikoma-shi
Saitama Medical University Hospital /ID# 258144
Iruma-gun
Ise Red Cross Hospital /ID# 222018
Ise-shi
Fujikawa Clinic /ID# 221135
Kanzaki-gun
Kariya Toyota General Hospital /ID# 239046
Kariya-shi
Watanabe Clinic /ID# 261352
Kasaoka-shi
Hospital of the University of Occupational and Environmental Health, Japan /ID# 255088
Kitakyushu-shi
Takano Kids Clinic /ID# 251656
Kobe
Aoyama Clinic /ID# 261942
Koriyama-shi
Kumamoto Shinto General Hospital /ID# 223245
Kumamoto
Kurume University Hospital /ID# 224112
Kurume-shi
Kyoto Shimogamo Hospital /ID# 233903
Kyoto
University Hospital Kyoto Prefectural University of Medicine /ID# 229599
Kyoto
Gunma University Hospital /ID# 231700
Maebashi
Machida Clinic /ID# 238744
Maebashi
Tsukada Clinic /ID# 255152
Maibara-shi
Aizawa Hospital /ID# 223247
Matsumoto-shi
Matsuyama Red Cross Hospital /ID# 239387
Matsuyama
Kousei General Hospital /ID# 249395
Mihara-shi
Misawa Municipal Misawa Hospital /ID# 229544
Misawa-shi
Meijo Hospital /ID# 250955
Nagoya
Nagoya City University Hospital /ID# 238745
Nagoya
Nagoya University Hospital /ID# 226746
Nagoya
Heartlife Hospital /ID# 249394
Nakagami-gun
Nakatsu Municipal Hospital /ID# 233390
Nakatsu-shi
Japanese Red Cross Narita Hospital /ID# 261349
Narita-shi
Oita Cardiovascular Hospital /ID# 239725
Ōita
Kitano Hospital /ID# 255150
Osaka
Yumura Clinic /ID# 254478
Osaka
National Hospital Organization Sagamihara National Hospital /ID# 221136
Sagamihara-shi
Saitama Children's Medical Center /ID# 227633
Saitama-shi
Miyagi Children's Hospital /ID# 258143
Sendai
National Center for Child Health and Development /ID# 225293
Setagaya-ku
Shikoku Central Hospital of the Mutual Aid /ID# 230273
Shikokuchūō
Shirakawa Kosei General Hosp. /ID# 240816
Shirakawa-shi
Osaka University Hospital /ID# 256174
Suita-shi
Heisei Hidaka Clinic /ID# 231758
Takasaki
Mie University Hospital /ID# 233864
Tsu
University of tsukuba Hospital /ID# 267373
Tsukuba
Yamaguchi University Hospital /ID# 262655
Ube-shi
Shonai Hospital /ID# 232294
Yamagata
Kawaguchi Clinic /ID# 226843
Yokohama
Tottori University Hospital /ID# 227634
Yonago-shi
Ishibashi Clinic /ID# 258148
Yonezawa-shi
Time Frame
Start Date: 2019-12-26
Completion Date: 2024-08-01
Participants
Target number of participants: 50
Treatments
Maviret Participants
Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
Related Therapeutic Areas
Sponsors
Leads: AbbVie